DB05179ExperimentalSmall molecule
DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
- Primary indication
- Investigated for use/treatment in parkinson's disease.Curator reviewed
- Code names
- DLO6002
Which companies are running trials of DLO6002, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account